The Physician’s Role in Treating Newly Diagnosed Patients with Myeloma
Audio is streamed directly from the publisher (media.blubrry.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Recorded on September 10, 2021
Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon.
Assistant Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, NY
This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.